Hormone Therapy News

The severity of postmenopausal vulvovaginal symptoms can be improved with a vaginal estradiol or moisturizer; however, these treatments do not offer additional benefit compared with placebo, according to a study published in JAMA Internal Medicine.

CHICAGO — Perimenopausal women treated with once-daily oral micronized progesterone experienced reductions in vasomotor symptoms and intensity, with no serious adverse effects, compared with placebo, leading researchers to call for further research on the potential of this therapy in the perimenopausal population.

CHICAGO — An oral contraceptive pill containing dimethandrolone undecanoate was safe when used for 28 days in healthy men, with no evidence of serious adverse events or significant changes in mood, sexual function, vital signs or heart function, according to new data presented here.

CHICAGO — At least four hormonal and two nonhormonal contraceptives for use by men are in the clinical pathway, with first-in-man studies begun or completed, and testing for safety, effectiveness and reversibility underway, Diana Lynn Blithe, PhD, announced during a presentation at the Presidential Plenary session here.

CHICAGO — New evidence, recent improvements in testosterone measurements and growing public interest encouraged the Endocrine Society to update its testosterone treatment guideline, which was last released in 2010.

CHICAGO — Young female athletes with normal weight and no or irregular menstrual periods reported fewer disordered eating behaviors, diminished drive for thinness and less body dissatisfaction after receiving 12 months of estrogen therapy, according to findings of a cross-sectional study and a randomized controlled trial reported here.

The FDA has approved an expanded indication for the growth hormone injection somatropin for the treatment of idiopathic short stature and Prader-Willi syndrome in children, Novo Nordisk announced in a press release.

Postmenopausal women using menopausal hormone therapy for at least 3 years were not at increased risk for adverse, subclinical changes in cardiac structure or function compared with women never prescribed the therapy, study data show.

Men aged at least 65 years receiving testosterone injections had an increased risk for cardiovascular events, including myocardial infarction, stroke or unstable angina, within 7 days of administration, but the risk was not increased in younger men, study data show.

Children with congenital adrenal hyperplasia tend to have lower bone mineral density compared with healthy children, but body composition is similar, according to findings published in Clinical Endocrinology.